Notable progress with antibody-drug conjugates from Seattle Genetics and Immunomedics drove the biggest Esmo share price moves.
All the attention is on aducanumab, but yesterday’s deal with Denali is a reminder that Biogen has other irons in the fire.
Roche must believe that Blueprint Medicines’ Ret inhibitor pralsetinib has a safety edge over Lilly’s Retevmo.
Last month the FDA greenlit four oncology approvals early and the first GnRH antagonist in uterine fibroids.
An early look at data from the huge cancer conference boosts Allogene and Immunogen, while Arvinas and Cytomx suffer.
Astrazeneca’s Lynparza is due US approval decisions in prostate and ovarian cancers, while Bristol's Opdivo’s fate will be determined in lung cancer.